{"doi":"10.1016/j.urolonc.2022.03.017","title":"Reduced CDH16 expression is linked to poor prognosis in clear cell renal cell carcinoma 16","abstract":null,"journal":"Urologic Oncology: Seminars and Original Investigations","year":2022,"id":616481,"datarank":0.20794415416798362,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"self_citation_contribution":0.20794415416798362,"citation_network_contribution":0.0,"self_endowment_contribution":0.20794415416798362,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1589446,"name":"Henrietta Csomós","orcid":null,"position":1,"is_corresponding":false},{"id":1265680,"name":"Christian Bernreuther","orcid":"0000-0003-3939-322X","position":2,"is_corresponding":false},{"id":1589449,"name":"Franziska Büscheck","orcid":null,"position":3,"is_corresponding":false},{"id":1589450,"name":"Christoph Fraune","orcid":null,"position":4,"is_corresponding":false},{"id":14062,"name":"Ronald Simon","orcid":"0000-0003-0158-4258","position":5,"is_corresponding":false},{"id":14011,"name":"Guido Sauter","orcid":"0000-0002-9024-4978","position":6,"is_corresponding":false},{"id":694632,"name":"Stefan Steurer","orcid":null,"position":7,"is_corresponding":false},{"id":1589451,"name":"Till Eichenauer","orcid":null,"position":8,"is_corresponding":false},{"id":1589452,"name":"Roland Dahlem","orcid":null,"position":9,"is_corresponding":false},{"id":1537623,"name":"Margit Fisch","orcid":null,"position":10,"is_corresponding":false},{"id":1589453,"name":"Silke Riechardt","orcid":null,"position":11,"is_corresponding":false},{"id":1360721,"name":"Michael Rink","orcid":null,"position":12,"is_corresponding":false},{"id":13819,"name":"Sarah Minner","orcid":"0000-0003-0765-3568","position":13,"is_corresponding":false},{"id":1589456,"name":"Doris Höflmayer","orcid":null,"position":14,"is_corresponding":false},{"id":1589445,"name":"Maximilian Lennartz","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Reduced CDH16 expression is linked to poor prognosis in clear cell renal cell carcinoma 16","abstract":"<h4>Objective</h4>Cadherin-16 (CDH16) is a member of the cadherin superfamily which is also termed kidney specific cadherin (ksp-cadherin) because of its preferred expression in the normal kidney where it plays a pivotal role in tubulus formation during embryonal development. However, little is known about the prognostic role of CDH16 in renal cell carcinomas.<h4>Methods and material</h4>CDH16 protein was analyzed by immunohistochemistry in more than 1,300 renal cell carcinomas (RCCs) in a tissue microarray format.<h4>Results</h4>A CDH16 positivity was found in 81% of 1,115 interpretable tumors. Staining was weak in 34%, moderate in 32% and strong in 15% of tumors. CDH16 positivity was more common in oncocytomas (99% positive) and chromophobe carcinomas (94%) than in papillary (73%) and clear cell RCCs (82%; P < 0.0001). In clear cell RCC, reduced CDH16 staining was significantly linked to high-grade (P < 0.0001), advanced pT stage (P = 0.0452), distant metastasis (P = 0.0003) as well as to shortened recurrence free (P < 0.0001), overall (P = 0.0002), and tumor specific survival (P = 0.0092). In a multivariate analysis including pT, pN, ISUP grade, and M status, CDH16 expression loss was an independent prognostic parameter for overall (P = 0.0016) and tumor specific survival (P = 0.0218) in clear cell RCC. Unequivocal associations with tumor phenotype and prognosis were not seen in papillary RCC.<h4>Conclusion</h4>Our data demonstrate that reduction of CDH16 expression is a strong and potentially clinically useful independent predictor of poor prognosis in clear cell RCC.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"35606285","pmcid":null,"openalex_id":null,"authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"hybrid","license":"cc-by","oa_locations":[{"url":"https://www.sciencedirect.com/science/article/pii/S1078143922001089/pdf","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1078143922001089?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1078143922001089?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.urolonc.2022.03.017","host_type":"Unpaywall"}],"fields_of_study":[],"mesh_terms":["Humans","Adenoma, Oxyphilic","Carcinoma, Renal Cell","Kidney Neoplasms","Cadherins","Prognosis","Biomarkers, Tumor"],"keywords":["Renal cell carcinoma","tissue microarrays","Cdh16"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-02T23:00:54.754518Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}